In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including: Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer Results of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant disease How R-DXd may be incorporated into the treatment paradigm Other investigational CDH6-targeting ADCs: CUSP06, SIM0505 Presenters: Kathleen N. Moore, MD, MS, FASCO Deputy Director and Cancer Therapeutics Co-Lead Stephenson Cancer Center at the University of Oklahoma Professor Department of OB/Gyn ASCO BOD Oklahoma City, Oklahoma Isabelle Ray-Coquard, MD, PhD President of the Gineco Group Centre Leon Bérard Reshape Lab Inserm u1290 Université Claude Bernard Lyon Est Lyon, France Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. Link to full program: https://bit.ly/43PXoeP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
